WorkflowQuality Operations & CAPA

FDA 483 Response for Drug GMP Inspections

A Form 483 response that checks each sentence of an observation against your records, traces how far it reaches across lots, batches and clients, and has a challenger read the draft as FDA's reviewer would before named people sign it.

See one observation answered screen by screen ↓
Watch with transcript →
The problem

The investigator writes down examples, and FDA judges the whole extent

A response that arrives within fifteen business days of the form gets a detailed review before FDA decides whether to issue a warning letter. At a drug substance contract manufacturer, one observation can reach shared reactors, a shared solvent recovery unit, one QC lab and several clients' products. Yet the response is usually written in a word processor from system exports, by the people who sat in the inspection, and its extent is the cited examples plus whatever someone remembers.

FDA's published warning letters call responses inadequate when they fix only the cited examples, skip the retrospective review, assess no material already used or shipped, name no interim control or attach no evidence. Commitment dates go into the letter before their owners have seen them, each client's part is pieced together afterward, and the commitments end up in a spreadsheet until the next inspection finds the same gap.

Built forQA compliance leadsHeads of qualityPlant QA headsSite headsCAPA owners

The Problem Today

An answer that covers only the examples on the form leaves other lots, batches and clients for FDA to find.

15
business days for a response FDA reviews before it decides published
2,837
drug inspection observations in FDA's FY2025 data file published

Pieced together from exports

  • Form text
  • Lot issues
  • Logbooks
  • Client mail
  • Dates promised before owners agreeCommitments carry dates the person doing the work never accepted
  • Clients told after the letterEach client's part assembled late, by hand

The Solution

  1. Each sentence checked firstEvery claim on the form tested against the record it names
  2. The whole extent tracedEvery affected lot, the batches made with it and where each one is now
  3. Read as FDA's reviewer wouldA challenger finds the gaps, the team's own overclaim included
  4. Signed, then keptThe QA head signs each section; each promise is tracked to its proof

Built-in controls

  • No one signs off their own work
  • A date enters the letter only after its owner accepts
  • Each client reads only its own products

What You Get

Investigators and clients see a site that answers the whole extent and keeps the dates it gave.

  • A first response written like a veteran'sFDA's reviewer questions are built into each draft
  • Each client hears its part firstIts own batches only, under its own quality agreement
  • Promises kept on their datesUpdate letters drafted on the day each falls due
Features

Form 483 response to one recovered-solvent observation, claim by claim

The response coordinator, the plant QA head, CAPA owners and the client quality liaison use them on one drug substance site's observation about recovered solvents, three business days before the response is due.

demoSample data throughout: the CDMO, its clients, the people, lots, batches, records and dates.

  1. 01Claims checked

    Form 483 observations read sentence by sentence and checked against records

    • The observation as the form prints it. Each lettered sentence becomes a claim, so the response answers what the investigator wrote rather than what the team remembers.
    • A verdict chip on each claim. Matches, needs context or not found, each chip opening the record the agent read, so no sentence of the reply contradicts a record.
    • The answer built in the order FDA reads it. What was found, how far it reaches, the correction, the systemic fix, the interim control, exhibits and commitments, each sentence cited.
    • The business-day clock in the corner. Days left, holidays excluded, and the internal date for signed sections stay in view while the coordinator works.
  2. 02Not found

    A claim the batch record contradicts, answered with that record

    • Not found, never called wrong. The agent reports only what the batch record shows; a person decides how the reply to FDA is worded.
    • The record attached as an exhibit. The charge record goes into the response, so a disagreement is answered with data instead of argument.
  3. 03Extent

    Extent of an observation traced across every lot, batch and client

    • Lots to batches to where each batch is now. Released, supplied to the next plant, shipped or held: each batch's status shows what the product-impact assessment must cover.
    • Scanned paper logbooks read too. The scanned recovery logbook is read beside the ERP issue records, so lots logged only on paper are in the extent too.
    • Interim control beside the extent. The hold placed by the plant QA head at the close-out shows what it blocks and since when.
    • Scope by client and solvent. A filter shows each client's batches apart, the same cut its notice is built from.
  4. 04FDA's reviewer

    A challenger reads the draft as FDA's reviewer and flags the team's overclaim

    • Points drawn from warning letter themes. Beyond the cited examples, product already shipped, interim control, evidence and owner-accepted dates each show whether the draft holds up.
    • The team's own sentence checked against its exhibit. Each sentence the team wrote is held against the exhibit it cites, so a claim wider than the testing behind it is cut back before signing.
    • Each point answered or given to a person. The plant QA head cannot sign the section while any point is open.
  5. 05Scope decision

    Observation scope widened by a person, with the reason on the record

    • What widening adds, shown before deciding. Lots, batches, the client affected and the change control behind them appear before the coordinator chooses.
    • Keeping something out needs a reason. Narrowing scope takes a reason code, and a typed note waits until the plant QA head has read it.
  6. 06Owner's date

    CAPA commitment dates accepted or moved by their owner before FDA sees them

    • Asked of the owner. The coordinator asks the owner, and the owner accepts or moves the date in their own session.
    • A moved date carries its reason. The reason comes from a fixed list and travels with the commitment, so the letter promises a date the person doing the work accepted.
  7. 07Response letter

    Response letter sections signed by the QA head after opening the exhibits

    • Contents, summary table and one section per observation. Investigation, CAPA and commitments for each observation sit where FDA's reviewer looks for them.
    • Sampled exhibits opened before signing. The plant QA head opens the extent table and the test results personally, and the preparer cannot sign a section.
    • Executive signatures come last. The plant head and the head of quality sign once every section is signed, as the people who commit the resources.
  8. 08Client notices

    Inspection findings notice for each client, limited to its own products

    • One notice per quality agreement clause. Each client hears its part under the clause it signed, before its own reviewers or FDA ask.
    • Redacted to the client's own products. One client never reads another client's batches, products or name.
    • Filing impact beside the notices. Where a fix changes a specification in a client's filing, the client decides its reporting category; where the site holds the drug master file, the site amends it.
  9. 09Commitments

    FDA commitments tracked to proof, with update letters drafted on their dates

    • Open commitments across inspections. Owner, due date, days left and state sit in one queue for this response and an earlier EU GMP report.
    • Update letters drafted on schedule. Each update to FDA is drafted for its promised date until every commitment is proven.
    • Closed after a second person opens the proof. An owner cannot close their own commitment; the checker opens the proof record first.

The coordinator prepares, the plant QA head signs, owners set their own dates

One person runs the response; the quality unit signs it; the people who will do the work decide when.

QA compliance leads

Coordinate the response and keep each commitment after it goes out

  • Each claim checked before writing
  • The full extent, paper logbooks included
  • Dates their owners have accepted
Plant QA heads

Sign each observation's section and each client notice

  • The sampled exhibits to open first
  • No signature while a point is open
  • Interim holds placed by a person
Heads of quality

Sign the letter and approve the rules the team learns

  • Repeat findings named before FDA names them
  • Learned rules wait for their signature
  • FDA and EU reports in one tracker
CAPA owners

Accept or move commitment dates and attach the proof

  • No date promised on their behalf
  • A fixed list of reasons to move one
  • Proof checked by a second person
More screens

Last year's internal audit found the same gap, and the response says so

Around the letter: the inspection history, the exhibits, what the team has learned, who did what, and the settings.

A repeat finding linked to its earlier auditAuthority inspections and internal audits across five plants; the EU GMP report keeps its own grading, and a repeat links to the audit that scoped its fix too narrowly.
Each exhibit tied to its source record and its readerEach exhibit with its source record, whether it is sampled for the signer, and who has opened it so far.
A correction becomes a proposed ruleRulings by quality leaders turn into rules only with the head of quality's approval, and one proposed today is waiting.
The owner's date change, in their own sessionWho widened the extent, which point raised what, the toluene decision and the owner's date change, each with its record and session; counsel's notes stay out of the export.
Looser settings wait for the head of qualityThe clock, the internal target, the reviewer lenses and sampled exhibits per observation; a tighter change applies at once.

demoSample data, from the working solution.

The challenger attacks the draft; other agents and people answer it

Each agent hands its work to the next by name, and each decision ends with a person.

Claim splitter

Splits each observation into the claims it makes, sentence by sentence, in the investigator's own words.

  • Rewrites or softens no sentence
Record checker

Opens the record each claim names and marks it matches, needs context or not found.

  • Calls no claim wrong
  • Sends each not found to a person
Extent tracer

Follows lots through ERP issues and scanned logbooks to every batch, product and client, and where each batch is now.

  • Narrows no scope silently
  • Places no hold and decides no disposition
Response writer

Drafts each section in reviewer order, numbers the exhibits and writes commitments with accepted dates.

  • Invents no date or result
  • Signs nothing
Challenger

Reads the draft as FDA's response reviewer and checks the team's own sentences against their exhibits.

  • Leaves each point to the writer, the tracer or a person
  • Closes no point
Notice drafter

Drafts each client's part under the clause of that client's agreement, limited to its products.

  • Sends nothing
  • Puts no client's batch in another's notice
Commitment keeper

Watches each commitment after the response goes out, asks owners for evidence and drafts update letters.

  • Marks no commitment closed

No agent places a hold, promises a date, signs or closes a commitment

Wording a disagreementThe record checker reports not found in our records with the record it searched; a person words the reply to FDA.
Placing a holdThe plant QA head places holds and quarantines; the agents attach the hold record as an exhibit.
Promising a dateNo commitment date enters the letter until its owner accepts it.
Deciding a batchDisposition stays with the plant QA head; release to market is the client's decision.
Closing a commitmentA second person opens the proof first, and an owner cannot close their own.

What QA teams ask about a Form 483 response

What is a Form 483 response?

A Form 483 response is the site's written answer to the observations an FDA investigator issues at the close of an inspection. Here agents check each sentence of an observation against the records, trace how far it reaches, and draft the answer in the order FDA's reviewer reads it; named people sign it.

When is the answer to a Form 483 due?

FDA gives a detailed review to a response it receives within fifteen business days of the form, before it decides whether to issue a warning letter. The clock here counts business days from the form's date with federal holidays excluded, and an internal target asks for signed sections two business days earlier.

How far must the investigation reach?

Past the cited examples. FDA's draft guidance on responding to Form 483 observations asks a site to check whether a deficiency affects other drugs, processes, facilities and contract organizations. Here the extent tracer follows each affected lot to every batch made with it and to where that batch is now.

Does each client see the whole response?

No. Each client gets a notice with only its own products and batches, under the clause of its own quality agreement, prepared by the client quality liaison and signed by the plant QA head.

Who signs the response?

The plant QA head signs each observation's section after opening its sampled exhibits, the coordinator signs as preparer, and the letter carries the head of quality's and the plant head's signatures as executive management. No signer checks their own work.

Does it handle an EU GMP inspection report?

It tracks one the same way: the deficiencies with their critical, major and other grading, the commitments made and the proof behind each. The sentence-by-sentence answer is for the Form 483.

What happens after the response goes out?

The commitment keeper watches each commitment, asks owners for evidence and drafts update letters on the promised dates. A commitment closes only when a second person has opened its proof.

Bring an observation
you answered last year.

Send one closed observation with the records behind it, and we will show its claims checked and its extent traced.